SCHEMBL19084552

SCHEMBL19084552

Cc1nn2c(=O)cc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 5/20 0.53
MAPT P10636 5/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
PGR P06401 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
ALPI P09923 1/20 0.36
GAA P10253 3/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CDC7 O00311 1/20 0.35
MAPK1 P28482 1/20 0.35
CCR6 P51684 1/20 0.35
PDE2A O00408 1/20 0.35
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084553 0.88 MAPT (0.54) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084539 0.85 PSD (0.52) PSDMAPTMEN1HTTKMT2A
SCHEMBL13516359 0.84 PSD (0.48) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084536 0.84 PSD (0.48) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084664 0.82 PSD (0.51) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084608 0.82 PSD (0.48) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084599 0.80 PSD (0.52) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084648 0.79 PSD (0.53) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084684 0.77 PSD (0.53) PSDMAPTMEN1HTTKMT2A
SCHEMBL19084688 0.76 PSD (0.51) PSDMAPTMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885MAPT 2995/4885MEN1 2915/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885MAPT 2995/4885MEN1 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.